Alcon Inc. (NYSE: ALC) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 43.26 | EPS (ttm) | 1.66 | Insider Own | - | Shs Outstand | 487.70M | Perf Week | 4.16% |
| Market Cap | 35.02B | Forward P/E | 18.50 | EPS next Y | 3.88 | Insider Trans | - | Shs Float | 486.14M | Perf Month | 6.96% |
| Enterprise Value | 38.73B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 2.68% | Perf Quarter | 12.41% |
| Income | 816.01M | P/S | 3.31 | EPS this Y | 106.28% | Inst Trans | - | Short Ratio | 6.06 | Perf Half Y | -8.37% |
| Sales | 10.58B | P/B | 1.57 | EPS next Y | 14.06% | ROA | 2.56% | Short Interest | 13.01M | Perf YTD | -8.88% |
| Book/sh | - | P/C | 15.40 | EPS next 5Y | 14.04% | ROE | 3.69% | 52W High | 92.43 -20.57% | Perf Year | -14.63% |
| Cash/sh | - | P/FCF | 21.34 | EPS past 3/5Y | 42.80% - | ROIC | 3.68% | 52W Low | 63.23 16.12% | Perf 3Y | -12.53% |
| Dividend Est. | 0.36 (0.49%) | EV/EBITDA | 16.39 | Sales past 3/5Y | 6.06% 8.77% | Gross Margin | 54.95% | Volatility | 1.88% 1.84% | Perf 5Y | -1.36% |
| Dividend TTM | 0.36 (0.49%) | EV/Sales | 3.66 | EPS Y/Y TTM | -19.51% | Oper. Margin | 12.31% | ATR (14) | 1.55 | Perf 10Y | - |
| Dividend Ex-Date | May 06, 2026 | Quick Ratio | 1.39 | Sales Y/Y TTM | 6.76% | Profit Margin | 7.71% | RSI (14) | 61.19 | Recom | 2.54 |
| Dividend Gr. 3/5Y | 17.60% - | Current Ratio | 2.20 | EPS Q/Q | 16.44% | SMA20 | 3.86% | Beta | 0.85 | Target Price | 82.00 |
| Payout | 19.70% | Debt/Eq | 0.24 | Sales Q/Q | 7.28% | SMA50 | 6.23% | Rel Volume | 1.00 | Prev Close | 71.81 |
| Employees | 25,000 | LT Debt/Eq | 0.21 | Earnings | Aug 10 | SMA200 | -3.89% | Avg Volume | 2.18M | Price | 73.42 |
| IPO Date | Apr 09, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.79% 0.57% | Net Debt/EBITDA | 1.57 | Volume | 2,180,219 | Change | 2.24% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Mizuho | Outperform | $105 → $80 |
| Jul-02-26 | Reiterated | Argus Research | Buy | $90 → $85 |
| May-08-26 | Reiterated | Barclays | Equal Weight | $86 → $78 |
| May-06-26 | Reiterated | Stifel Nicolaus | $82 → $70 | |
| Mar-09-26 | Reiterated | Stifel Nicolaus | $80 → $82 | |
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight | $105 → $97 |
| Jan-09-26 | Reiterated | Stifel Nicolaus | $85 → $80 | |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold | |
| Dec-11-25 | Downgrade | B of A Securities | Buy → Underperform | |
| Nov-14-25 | Reiterated | Bernstein | Outperform | $76 → $101 |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10,581 | 10,401 | 9,911 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,767 | 4,656 | 4,399 | — | — | — | — | — | — | |
| Gross Profit | 5,814 | 5,745 | 5,512 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 3,480 | 3,449 | 3,250 | — | — | — | — | — | — | |
| Research and Development | 1,008 | 990 | 876 | — | — | — | — | — | — | |
| Other Operating Expense | 24 | -54 | -27 | — | — | — | — | — | — | |
| Operating Income | 1,303 | 1,360 | 1,413 | — | — | — | — | — | — | |
| Interest Expense | 206 | 204 | 186 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -116 | 4 | 29 | — | — | — | — | — | — | |
| Net Income Before Taxes | 981 | 1,160 | 1,256 | — | — | — | — | — | — | |
| Income Taxes | 166 | 180 | 238 | — | — | — | — | — | — | |
| Consolidated Net Income | 815 | 980 | 1,018 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 815 | 980 | 1,018 | — | — | — | — | — | — | |
| Net Income | 815 | 980 | 1,018 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.66 | 1.99 | 2.06 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.66 | 1.99 | 2.06 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.65 | 1.98 | 2.05 | — | — | — | — | — | — | |
| EBITDA | 2,363 | 2,351 | 2,676 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 44.50 | 39.80 | 41.41 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.38 | 3.75 | 4.23 | — | — | — | — | — | — | |
| Gross Margin | 54.95 | 55.24 | 55.61 | — | — | — | — | — | — | |
| Operating Margin | 12.31 | 13.08 | 14.26 | — | — | — | — | — | — | |
| Net Margin | 7.70 | 9.42 | 10.27 | — | — | — | — | — | — | |
| Shares Outstanding | 487 | 495 | 494 | — | — | — | — | — | — | |
| Market Capitalization | 35,756 | 39,011 | 41,936 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |